{
  "id": "61f7d683882a024a10000036",
  "type": "factoid",
  "question": "Which enzyme is inhibited by Aramchol?",
  "ideal_answer": "Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32982112",
    "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
    "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
    "http://www.ncbi.nlm.nih.gov/pubmed/31013363",
    "http://www.ncbi.nlm.nih.gov/pubmed/34621052",
    "http://www.ncbi.nlm.nih.gov/pubmed/21044742",
    "http://www.ncbi.nlm.nih.gov/pubmed/34151243"
  ],
  "snippets": [
    {
      "text": "Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) in hepatocytes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although the primary end point of a reduction in liver fat did not meet the prespecified significance level with Aramchol 600\u2009mg, the observed safety and changes in liver histology and enzymes provide a rationale for SCD1 modulation as a promising therapy for NASH and fibrosis and are being evaluated in an ongoing phase 3 program.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A number of phase 3 clinical trials are currently ongoing including Elafibranor, a dual PPAR \u03b1/\u03b4 agonist, Cenicriviroc, a CCR2/CCR5 chemokine antagonist, the nuclear bile acid receptor FXR agonist obeticholic acid, Aramchol, a fatty acid bile acid conjugate that modulates SCD-1, and Resmetrion, a liver-specific THR-\u03b2 agonist. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31931543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) in hepatocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aramchol downregulated stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid \u03b2-oxidation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nclusions: Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing SCD1, and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. W",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "atherogenesis. The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic effects, will affect atheroge",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatoh",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid \u03b2-oxidation. Aramchol increased the ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "epatitis (NASH). Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "d increased PPARG mRNA expression.Conclusions: Aramchol downregulates SCD1 and elevates PPARG in HSCs, reduci",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "g COL1A1 and ACTA2 mRNAs and COL1A1 secretion. These data suggest a direct inhibitory effect of Aramchol in HSCs through SCD1 inhibition, as part of a broader impact on both fibrogenic genes a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents an",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34621052",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "atitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated stearoyl-CoA desaturase 1 (SCD1), a key enzyme involved in triglyceride biosynthesis wh",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29159325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sis. The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21044742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31013363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of stea",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32982112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cing COL1A1 and ACTA2 mRNAs and COL1A1 secretion. These data suggest a direct inhibitory effect of Aramchol in HSCs through SCD1 inhibition, as part of a broader impact on both fibrogenic gene",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ich catalyses cholesterol synthesis. In phHeps, Aramchol also reduced SCD1 and increased PPARG mRNA expression.Conclusions: Aramchol downregulates SCD1 and elevates PPARG in HSCs, red",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34151243",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "hepatic stearoyl-CoA desaturase 1"
}